Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. We show 10 historical shares outstanding datapoints in our CYT shares outstanding history coverage, used to compute CYT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYT market cap history over the course of time is important for investors
interested in comparing CYT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYT versus a peer is one thing; comparing
CYT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYT can fluctuate over the course of history.
With this page we aim to empower investors researching CYT by allowing them to research the CYT market cap history. |
Free CYT Email Alerts:
Video: The Importance of Market Cap
